Very Low LeverageHaving no recorded debt is a durable financial strength: it reduces immediate bankruptcy risk, lowers fixed financing costs, and preserves flexibility to structure future partner deals or equity raises. For a pre-revenue biotech, low leverage supports optionality during long development timelines.

Improving Cash BurnSustained reduction in operating cash burn indicates better cost discipline and modest operational efficiency gains. Over a multi-quarter horizon this extends runway, reduces near-term financing frequency, and increases the chance management can progress programs further before dilutive capital events.

Focused R&D And Partner StrategyA concentrated therapeutic focus combined with an explicit partnering strategy is a durable business model for small biotechs: it builds deep domain expertise, improves attractiveness to larger pharma, and allows the company to de-risk late-stage costs by out-licensing or co-developing assets rather than self-funding full commercialization.

Bears Say

Pre-revenue With Persistent LossesNo revenue and repeated operating losses leave the company dependent on external capital to progress clinical programs. Over months this structural funding need increases dilution risk and constrains strategic choices, limiting the ability to scale operations or self-fund pivotal trials without partners.

Eroded Equity CushionA sharply reduced equity base is a durable weakness: it reflects cumulative losses and leaves little capital buffer against adverse events. This materially raises the probability of near-term fundraising, increases dilution risk, and weakens negotiating leverage with partners or investors.

Extremely Small Operating ScaleA two-person headcount is a structural constraint on execution: internal capacity for clinical program management, regulatory work, and commercial planning is minimal. Reliance on contractors and partners raises execution risk, slows program cadence, and can increase long-term costs and coordination complexity.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.33 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €3.48M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Feb 25, 2026 which is in 3 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on Nov 26, 2025. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.